Welcome to our dedicated page for Nano-X Imaging Ltd. SEC filings (Ticker: NNOX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NANO-X IMAGING LTD filings document foreign private issuer disclosures for a medical imaging technology company with ordinary shares listed under NNOX. Recent Form 6-K reports cover financial results, GAAP and non-GAAP measures, business updates, FDA 510(k) clearance for TAP2D on Nanox.ARC and Nanox.ARC X systems, and commercial developments involving Nanox.ARC deployment.
The filing record also includes capital-structure and governance disclosures, including a registered direct offering of ordinary shares, material agreements, incorporation of exhibits into Form F-3 and Form S-8 registration statements, and annual general meeting proxy materials. These documents describe shareholder voting matters, financing activity, operating results, regulatory updates and corporate reporting controls for the company.
Nano-X Imaging Ltd. director Kainan Noga purchased 33,000 ordinary shares on July 28, 2026 at $0.9000 per share in an open-market or private transaction. He also reports existing stock options over 12,505, 50,000 and 10,000 shares at exercise prices of $64.6100, $17.6300 and $11.5200, plus 794 ordinary shares held indirectly through I.B.L. Business Consulting Ltd. Additional ordinary shares are reported as underlying restricted share units granted December 10, 2025 that vest in twelve equal monthly installments.
Nano-X Imaging Ltd. CFO Daniel Ran reported a disposition of 1,000 Ordinary Shares back to the issuer on 2026-07-29 at $0.89 per share. After this issuer-related transaction, Ran directly holds 5,950 Ordinary Shares. The transaction is classified as a disposition to the issuer and was not marked as made under a Rule 10b5-1 trading plan.
A shareholder of Nano-X Imaging Ltd. (NNOX) has filed a notice of proposed sale of ordinary shares. The filing lists ordinary shares to be sold through Etrade and Altshare, with indicated quantities of 1,000 and 5,950 shares and aggregate market values of 880.00 and 5,236.00, respectively, to be sold on Nasdaq in late July 2026.
The shareholder reports that the 1,000 shares were acquired by purchase on 09/05/2025 through Etrade as a purchase in the open market, and that 5,950 shares were acquired via an RSU Grant on 04/16/2024. These details document how the securities were obtained prior to the planned sales.
Nano-X Imaging Chief Executive Officer Erez Meltzer, through his wholly owned company Oud Nof, purchased 36,000 ordinary shares on July 27, 2026 at $0.93 per share, reported as indirect ownership. The report also lists existing direct holdings of 60,584 shares and several vested and vesting stock option grants with exercise prices between $2.21 and $23.84, expiring from 2030 to 2034.
NANO-X Imaging Ltd. is registering an at-the-market offering of up to $53,900,000 of ordinary shares under its $100,000,000 shelf, to be sold from time to time through Cantor Fitzgerald & Co. and Mizuho Securities USA LLC as agents, for up to a 3% commission.
Based on a July 21, 2026 price of $1.08 per share, total shares outstanding could reach up to 119,508,190, subject to the current limit of 100,000,000 authorized ordinary shares, which may constrain full use of the ATM unless shareholders approve an increase. Net proceeds are intended for research and development, manufacturing activities, and general corporate purposes.
The company reports an accumulated deficit of $463 million as of March 31, 2026 and states that existing cash is not sufficient to support operations for at least one year, raising substantial doubt about its ability to continue as a going concern, making this capital-raising facility important to its liquidity plans.
NANO-X IMAGING LTD released preliminary, unaudited figures for the quarter ended June 30, 2026 and a brief business update. Revenue is expected at approximately $4.0 to $4.1 million, up from $3.0 million a year earlier, driven by teleradiology, imaging systems and AI software.
Teleradiology services contributed about $2.9 million, imaging systems and OEM services about $0.2 million, and AI and software solutions $1.0 million, mainly reflecting consolidation of Vaso Healthcare IT Corp. Cash, cash equivalents, short-term deposits and long-term restricted deposits were approximately $31.4 million at June 30, 2026 versus $60.0 million at December 31, 2025.
Management states that existing liquidity is not sufficient to fund operations for at least one year from the press release date, raising substantial doubt about the company’s ability to continue as a going concern. The company is pursuing capital-raising efforts and potential cost deferrals and is also evaluating possible impairment charges on certain long-lived assets and goodwill. This disclosure is incorporated by reference into its Form F-3 shelf registration and related July 23, 2026 prospectus supplement.
Nano-X Imaging Ltd provides a legal opinion from Meitar Law Offices covering the validity of the remaining $53.9 million of ordinary shares, par value NIS 0.01, that may be issued and sold from time to time under its at-the-market Controlled Equity Sales Agreement with Cantor Fitzgerald and Mizuho Securities.
These potential issuances are made pursuant to Nano-X’s effective shelf registration statement on Form F-3, filed March 13, 2026 and declared effective March 30, 2026, and a July 23, 2026 prospectus supplement. The materials are incorporated by reference into that registration framework and expressly do not themselves constitute an offer to sell shares.
Investor Moshe Moalem reports beneficial ownership of 5,263,161 Nano-X Imaging Ltd. ordinary shares, representing 7.56% of the outstanding class. This percentage is based on 69,609,485 ordinary shares outstanding as of December 31, 2025, as reported in the company’s annual report.
Moalem holds 4,266,430 ordinary shares directly and an additional 996,731 through Tanir Corporation BVI, a wholly owned and controlled entity. He has sole voting and sole dispositive power over all 5,263,161 shares, with no shared voting or dispositive power.
Nano-X Imaging reported first-quarter 2026 revenue of $4.3 million, up from $2.8 million a year earlier, driven mainly by teleradiology services of $3.1 million and $1.0 million from AI and software solutions. Despite improving gross loss, the company posted a GAAP net loss of $14.3 million and a non-GAAP net loss of $11.1 million.
Cash, cash equivalents, deposits and restricted deposits totaled $44.2 million as of March 31, 2026, down from $60.0 million at year-end, with negative operating cash flow of $14.0 million. Management states these resources are not sufficient for at least one year, raising substantial doubt about the company’s ability to continue as a going concern, and it is seeking additional financing that could dilute shareholders or add debt.
The company no longer expects to achieve its previously announced 2026 revenue target and plans to stop providing annual revenue guidance, citing unpredictable deployment and revenue-recognition timelines. It also discloses a newly filed securities class action in U.S. federal court related to prior disclosures, with no loss accrual recorded due to the early stage of the case.
Nano-X Imaging Ltd. director Alroy Erez sold 678 ordinary shares on June 10, 2026 at $1.65 per share in open-market transactions. A footnote explains that the reported sale of ordinary shares was used to cover tax liabilities arising from the vesting of restricted share units.
Following these transactions, Erez continues to hold ordinary shares tied to RSU grants, including 6,753 and 17,075 ordinary shares remaining or issuable under two separate awards. He also holds stock options over 10,000 ordinary shares at an exercise price of $11.52 expiring on December 31, 2033, and options over 50,000 ordinary shares at an exercise price of $17.63 expiring on December 28, 2032.